Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASGR1 | P07306 | 9/20 | 0.62 |
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.33 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18723059 | 0.85 | ASGR1 (0.63) | ASGR1 | |
| SCHEMBL18722934 | 0.82 | ASGR1 (0.59) | ASGR1 | |
| SCHEMBL18722902 | 0.82 | ASGR1 (0.62) | ASGR1 | |
| SCHEMBL18722972 | 0.80 | ASGR1 (0.61) | ASGR1NEU3 | |
| SCHEMBL23346074 | 0.77 | ASGR1 (0.42) | ASGR1 | |
| SCHEMBL17256336 | 0.76 | ASGR1 (1.00) | ASGR1NEU3HPSE | |
| SCHEMBL18723067 | 0.76 | ASGR1 (0.40) | ASGR1 | |
| SCHEMBL21249101 | 0.76 | ASGR1 (0.40) | ASGR1 | |
| SCHEMBL18722974 | 0.73 | ASGR1 (0.60) | ASGR1 | |
| SCHEMBL22021026 | 0.71 | ASGR1 (0.55) | ASGR1NEU3HPSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767301-B2 | Bi-functional molecules to degrade circulating proteins | YALE UNIVERSITY (US) | 2023-09-26 | — | — | US | disclosed |
| US-20210139436-A1 | Bi-functional Molecules to Degrade Circulating Proteins | YALE UNIVERSITY | 2021-05-13 | — | — | US | disclosed |
| US-10851367-B2 | Tissue-specific genome engineering using CRISPR-Cas9 | PFIZER INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10813942-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | PFIZER INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20190321382-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | PFIZER INC. (US) | 2019-10-24 | — | — | US | disclosed |
| US-10376531-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | PFIZER INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20170137801-A1 | TISSUE-SPECIFIC GENOME ENGINEERING USING CRISPR-CAS9 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-05-18 | — | — | US | disclosed |
| US-9617293-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | PFIZER INC. (US) | 2017-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767301-B2 | Bi-functional molecules to degrade circulating proteins | MIF, ASGR1, FCGR2A | ASGR1 2/4885NEU3 384/4885HPSE 274/4885 |
| US-10813942-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | ASGR1, MRGPRX2, LDLR | ASGR1 1/4885NEU3 264/4885HPSE 327/4885 |
| US-10851367-B2 | Tissue-specific genome engineering using CRISPR-Cas9 | ASGR1, LDLR, HAVCR2 | ASGR1 1/4885NEU3 55/4885HPSE 117/4885 |
| US-20190321382-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | ASGR1, MRGPRX2, LDLR | ASGR1 1/4885NEU3 264/4885HPSE 327/4885 |
| US-20210139436-A1 | Bi-functional Molecules to Degrade Circulating Proteins | MIF, ASGR1, FCGR2A | ASGR1 2/4885NEU3 384/4885HPSE 274/4885 |
| US-10376531-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | ASGR1, MRGPRX2, LDLR | ASGR1 1/4885NEU3 264/4885HPSE 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.